These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27924647)

  • 1. Introduction.
    Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):1. PubMed ID: 27924647
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.
    Matucci A; Cammelli D; Cantini F; Goletti D; Marino V; Milano GM; Scarpa R; Tocci G; Maggi E; Vultaggio A
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):3-10. PubMed ID: 27924646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?
    Wendling D; Verhoeven F; Guillot X; Prati C
    Expert Opin Drug Saf; 2017 Jan; 16(1):1-3. PubMed ID: 27737601
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 6. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
    Winger EE; Reed JL
    J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
    [No Abstract]   [Full Text] [Related]  

  • 7. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 8. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological therapy and neurological manifestations. What do we know?
    Tejera-Segura B; Ferraz-Amaro I
    Reumatol Clin; 2017; 13(2):102-106. PubMed ID: 27373584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].
    Faucherre M; Pazar B; So A; Aubry-Rozier B
    Rev Med Suisse; 2011 Jan; 7(277):75-6, 78-9. PubMed ID: 21309182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic.
    Russell AS; Rosenbaum JT
    J Rheumatol Suppl; 2010 May; 85():53-62. PubMed ID: 20436165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis associated with therapy against tumor necrosis factor alpha.
    Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
    Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
    [No Abstract]   [Full Text] [Related]  

  • 13. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor necrosis factor-alpha blocker induced tuberculosis.
    Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
    J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
    [No Abstract]   [Full Text] [Related]  

  • 15. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
    Haraoui B
    J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
    [No Abstract]   [Full Text] [Related]  

  • 16. Infection and anti-tumor necrosis factor-alpha therapy.
    Zandman-Goddard G
    Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
    [No Abstract]   [Full Text] [Related]  

  • 17. TNF antagonists and shingles: is vaccination advisable?
    Nisar MK; Ostor AJ
    Ann Rheum Dis; 2013 May; 72(5):e1. PubMed ID: 23456927
    [No Abstract]   [Full Text] [Related]  

  • 18. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.
    Carmona L; Descalzo MA; Ruiz-Montesinos D; Manero-Ruiz FJ; Perez-Pampin E; Gomez-Reino JJ;
    Rheumatology (Oxford); 2011 Jan; 50(1):85-92. PubMed ID: 20601654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
    Toussirot E; Pertuiset E; Kantelip B; Wendling D
    Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.